Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Di(Hydroxyethyl)Ether. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CA5A | P35218 | 1/20 | 0.47 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.31 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Di(Hydroxyethyl)Ether SCHEMBL787692 | 1.00 | TSHR (0.59) | TSHRMAPK1KMT2AMEN1CA5A | |
| Di(Hydroxyethyl)Ether SCHEMBL10582766 | 1.00 | TSHR (0.59) | TSHRMAPK1KMT2AMEN1CA5A | |
| Triethylene Glycol SCHEMBL989878 | 0.97 | KMT2A (0.61) | TSHRMAPK1KMT2AMEN1CA5A | |
| Triethylene Glycol SCHEMBL6292167 | 0.97 | KMT2A (0.61) | TSHRMAPK1KMT2AMEN1CA5A | |
| Tetraethylene Glycol SCHEMBL1773960 | 0.97 | KMT2A (0.61) | TSHRMAPK1KMT2AMEN1CA5A | |
| Triethylene Glycol SCHEMBL10582059 | 0.97 | KMT2A (0.61) | TSHRMAPK1KMT2AMEN1CA5A | |
| Di(Hydroxyethyl)Ether SCHEMBL27621023 | 0.86 | TSHR (0.43) | TSHRMAPK1KMT2AMEN1CA5A | |
| Di(Hydroxyethyl)Ether SCHEMBL28257194 | 0.86 | TSHR (0.56) | TSHRMAPK1KMT2AMEN1CA5A | |
| 2-Ethoxyethanol SCHEMBL10613720 | 0.85 | ALDH1A1 (0.67) | TSHRMAPK1KMT2AMEN1CA5A | |
| SCHEMBL4372008 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1087 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3433086-B1 | ENERGETIC MATERIALS | TNO (NL) | 2026-05-06 | — | — | EP | claimed |
| US-20260115188-A1 | METHODS OF TREATING CENTERAL NERVOUS SYSTEM DISORDERS COMPRISING ADMINISTERING DEUTERATED LUMATEPERONE AND A NITRIC OXIDE DONOR | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-04-30 | — | — | US | claimed |
| US-20260110607-A1 | TRANSPORT AND DETECTION OF EXPLOSIVE SAMPLES WITH MINIMIZED FALSE POSITIVES | ALTI LLC (US) | 2026-04-23 | — | — | US | claimed |
| US-12590249-B2 | Etchant composition | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2026-03-31 | — | — | US | claimed |
| US-12517047-B2 | Transport and detection of explosive samples | ALTI LLC (US) | 2026-01-06 | — | — | US | claimed |
| US-12478623-B2 | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-11-25 | — | — | US | claimed |
| US-20250237601-A1 | TRANSPORT AND DETECTION OF EXPLOSIVE SAMPLES | ALTI LLC | 2025-07-24 | — | — | US | claimed |
| US-20250236569-A1 | Lead-free Ballistic Modifier for Rocket Motor Propellants | USA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) | 2025-07-24 | — | — | US | claimed |
| US-20250011476-A1 | ARTICLES COMPRISING CROSSLINKED POLYMER NETWORK COMPRISING THIOETHER CROSSLINKS AND PROCESS OF MAKING AND USING SAME | US GOV AIR FORCE (US) | 2025-01-09 | — | — | US | claimed |
| EP-3969432-B1 | PROPELLANT POWDER GRAIN COMPRISING AT LEAST PARTIALLY OBTURATED CHANNELS | EURENCO FRANCE SAS (FR) | 2024-10-23 | — | — | EP | claimed |
| US-4339288-A | Gas generating composition | Stang, Peter (US) | 1982-07-13 | — | — | US | claimed |
| US-4336085-A | MODIFYING THE DETONATION VELOCITY | WALKER FRANKLIN E | 1982-06-22 | — | — | US | claimed |
| US-4304614-A | AMMUNITION, DYNAMIC LASERS, FUSES, WELDING | WALKER FRANKLIN E | 1981-12-08 | — | — | US | claimed |
| EP-0030429-A2 | Fuels and a method of running an engine using such fuels | AECI LIMITED (ZA) | 1981-06-17 | — | — | EP | claimed |
| US-4243442-A | Pre-solution preparation of double base propellant binder | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1981-01-06 | — | — | US | claimed |
| US-4239561-A | NITRATE ESTERS AND CUPRIC RESORCYLATE | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1980-12-16 | — | — | US | claimed |
| US-4092188-A | PLASTICIZED BINDER CONTAINING MONOPROPELLANT TO SMOOTH OUT BURNING RATE CURVE | LOVELACE ALAN M ACTING ADMINIS | 1978-05-30 | — | — | US | claimed |
| US-4051207-A | PROCESS FOR THE PRODUCTION OF PROPELLANT CHARGE POWDERS, ESPECIALLY NITROGUANIDINE POWDERS | DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) | 1977-09-27 | — | — | US | claimed |
| US-4002514-A | DOUBLE BASE; NITRAMINE OXIDIZER; TRIAMINOGUANIDINIUM-AZIDE OR -HYDRAZINIUM DIAZIDE | THE DOW CHEMICAL COMPANY (US) | 1977-01-11 | — | — | US | claimed |
| US-3977922-A | NITRO COMPOUNDS IN THERMOSETTING RESINS | NIPPON OILS AND FATS COMPANY LIMITED (JA) | 1976-08-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12590249-B2 | Etchant composition | ASIC1, NOS1, CA1 | TSHR 3365/4885MAPK1 579/4885KMT2A 1288/4885 |
| US-20260110607-A1 | TRANSPORT AND DETECTION OF EXPLOSIVE SAMPLES WITH MINIMIZED FALSE POSITIVES | TES, TNPO1, SLC2A1 | TSHR 3452/4885MAPK1 2109/4885KMT2A 4764/4885 |
| US-20260115188-A1 | METHODS OF TREATING CENTERAL NERVOUS SYSTEM DISORDERS COMPRISING ADMINISTERING DEUTERATED LUMATEPERONE AND A NITRIC OXIDE DONOR | HTR2C, DRD2, HTR2A | TSHR 118/4885MAPK1 1116/4885KMT2A 2953/4885 |
| US-12478623-B2 | Methods of treating central nervous system disorders comprising administering lumateperone and a nitric oxide donor | HTR2A, HTR2C, HTR5A | TSHR 450/4885MAPK1 1521/4885KMT2A 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.